This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Periclou A, Riccobene T, Kapás M, et al. Comment on: “Clinical pharmacokinetics of atypical antipsychotics: an update”. Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00795-9
Mauri MC, Paletta S, Di Pace C, et al. Clinical pharmacokinetics of atypical antipsychotics: an update. Clin Pharmacokinet. 2018;57(12):1493–528. https://doi.org/10.1007/s40262-018-0664-3.
Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195–235.
Nakamura T, Kubota T, Iwakaji A, et al. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther. 2016;10:327–38.
Carrothers T, Willavize S, Jaworowicz DJ, et al. Relationship of cariprazine plasma concentration to efficacy and safety in patients with schizophrenia or bipolar mania [poster]. American Psychiatric Association (APA) Annual Meeting; 14–18 May 2016; Atlanta. https://www.simulations-plus.com/resource/relationship-cariprazine-plasma-concentration-efficacy-safety-patients-schizophrenia-bipolar-mania/. Accessed 13 June 2019.
No external funding was used in the preparation of this reply.
Conflict of interest
Massimo Carlo Mauri has no conflicts of interest that are directly relevant to the contents of this reply.
About this article
Cite this article
Mauri, M.C. Reply to Periclou et al.: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”. Clin Pharmacokinet 58, 1217–1218 (2019). https://doi.org/10.1007/s40262-019-00796-8